Detalhe da pesquisa
1.
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Cancer Immunol Immunother
; 73(4): 72, 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38430405